- Home
- Equipment
- usa massachusetts
- diarrhea
Refine by
Diarrhea Equipment Supplied In Usa Massachusetts
5 equipment items found
Manufactured by:Finch Therapeutics Group, Inc. based inSomerville, MASSACHUSETTS (USA)
Our lead product candidate, CP101, is an orally administered, Complete Consortia product candidate initially targeting the prevention of recurrent CDI. The Centers for Disease Control and Prevention considers CDI to be one of the top three most urgent antibiotic resistant threats and the most common cause of healthcare associated infection in the United ...
Manufactured by:Akebia Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
As part of our mission, we’re working to address complications of kidney disease and we currently market AURYXIA (ferric citrate) in the U.S. for its two approved indications: The control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis; The treatment of iron deficiency anemia in adult patients with chronic kidney disease not on ...
Manufactured by:Finch Therapeutics Group, Inc. based inSomerville, MASSACHUSETTS (USA)
In collaboration with Takeda Pharmaceuticals, we are developing FIN-524 and FIN-525, orally administered, Targeted Consortia product candidates designed for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD), respectively. UC and CD are the two most common types of IBD, an autoimmune condition that causes inflammation of the gastrointestinal (GI) ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
Despite the widespread use of the 5-HT3 receptor antagonist anti-emetics such as Palonosetron (Aloxi; Eisai), Ondansetron (Zofran®; GSK), Granisetron (Kytril®; Roche Pharmaceuticals), and Dolasetron (Anzemet®; Aventis), CINV continues to be reported by up to 70% of adult patients receiving highly emetogenic chemotherapy agents and 58% of school-age and adolescent-age children ...
Manufactured by:Eagle Pharmaceuticals, Inc. based inWoodcliff Lake, NEW JERSEY (USA)
Indication: PEMFEXY is indicated in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). PEMFEXY is indicated as a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose disease has not progressed after four ...